Newly reported results
Setidegrasib (ASP3082) — KRAS G12D targeted protein degrader (phase I)
A Study of ASP3082 in Adults With Advanced Solid Tumors
- Phase
- Phase I
- Recruitment
- Recruiting
- Results maturity
- Interim analysis
- Publication
- Peer-reviewed
- Regulatory approval
- No regulatory approval
- NCT
- NCT05382559
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? An early clinical study tested a new drug that tries to destroy the harmful KRAS G12D protein in cancer cells. It is not standard care yet.
Why promising? First-in-class KRAS G12D degrader; provides a clinical signal for a major unmet need in pancreas cancer.
What is not proven? Approval; randomized superiority; long-term OS; class comparison versus MRTX1133.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
NCT05382559; NEJM 2026. NSCLC ORR ~36%, PDAC ORR ~24% (600 mg). Infusion reactions common. Numeric summary pending clinician review.
Cancer / population: Pancreas, Multiple / solid tumors — Önceden tedavi almış ileri solid tümörler (KRAS G12D); NSCLC ve PDAC alt analizleri
Intervention: Setidegrasib (IV, haftalık; RP2D 600 mg kohortları)
Primary endpoint: Güvenlik / DLTs / faz II doz
Source-verified summary: NEJM 2026: 600 mg cohort — NSCLC ORR 36% (n=45); metastatic PDAC ORR 24% (n=21), mPFS 3.0 mo, mOS 10.3 mo. Not registrational.
Limitations: Faz I; seçilmiş kohort; standart bakım değildir.